A PVDF Receiver for Ultrasound Monitoring of Transcranial Focused Ultrasound Therapy

Department of Imaging Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada.
IEEE transactions on bio-medical engineering (Impact Factor: 2.35). 09/2010; 57(9):2286-94. DOI: 10.1109/TBME.2010.2050483
Source: PubMed


Focused ultrasound (FUS) shows great promise for use in the area of transcranial therapy. Currently dependent on MRI for monitoring, transcranial FUS would benefit from a real-time technique to monitor acoustic emissions during therapy. A polyvinylidene fluoride receiver with an active area of 17.8 mm (2) and a film thickness of 110 mum was constructed. A compact preamplifier was designed to fit within the receiver to improve the receiver SNR and allow the long transmission line needed to remove the receiver electronics outside of the MRI room. The receiver was compared with a 0.5 mm commercial needle hydrophone and focused and unfocused piezoceramics. The receiver was found to have a higher sensitivity than the needle hydrophone, a more wideband response than the piezoceramic, and sufficient threshold for detection of microbubble emissions. Sonication of microbubbles directly and through a fragment of human skull demonstrated the ability of the receiver to detect harmonic bubble emissions, and showed potential for use in a larger scale array. Monitoring of disruption of the blood-brain barrier in rats showed functionality in vivo and the ability to detect subharmonic, harmonic, and wideband emissions during therapy. The receiver shows potential for monitoring acoustic emissions during treatments and providing additional parameters to assist treatment planning. Future work will focus on developing a multi-element array for transcranial treatment monitoring.

Full-text preview

Available from:
  • Source
    • "However, the nonlinear nature of bubble oscillations allows using the subharmonic to detect stable cavitation experimentally (Neppiras 1968, Mestas et al 2003, Vykhodtseva et al 1995, McLaughlan et al 2010). Subharmonic emissions from cavitation are well established theoretically (Eller and Flynn 1969, Prosperetti 1974, Katiyar and Sarkar 2011), and are known to correlate experimentally with several in vivo and in vitro bioeffects, such as ultrasound-enhanced thrombolysis (Prokop et al 2007), disruption of the blood brain barrier (O'Reilly and Hynynen 2010), chemotherapy drug release from micelles (Husseini et al 2005), and enhanced heating in focused ultrasound surgery (Sokka et al 2003). Thus knowledge of the threshold of subharmonic emissions could be used to gauge the potential for clinically beneficial bioeffects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanical index (MI) was formulated to gauge the likelihood of adverse bioeffects from inertial cavitation. However, the MI formulation did not consider bubble activity from stable cavitation. This type of bubble activity can be readily nucleated from ultrasound contrast agents (UCAs) and has the potential to promote beneficial bioeffects. Here, the presence of stable cavitation is determined numerically by tracking the onset of subharmonic oscillations within a population of bubbles for frequencies up to 7 MHz and peak rarefactional pressures up to 3 MPa. In addition, the acoustic pressure rupture threshold of an UCA population was determined using the Marmottant model. The threshold for subharmonic emissions of optimally sized bubbles was found to be lower than the inertial cavitation threshold for all frequencies studied. The rupture thresholds of optimally sized UCAs were found to be lower than the threshold for subharmonic emissions for either single cycle or steady state acoustic excitations. Because the thresholds of both subharmonic emissions and UCA rupture are linearly dependent on frequency, an index of the form I(CAV) = P(r)/f (where P(r) is the peak rarefactional pressure in MPa and f is the frequency in MHz) was derived to gauge the likelihood of subharmonic emissions due to stable cavitation activity nucleated from UCAs.
    Physics in Medicine and Biology 12/2012; 58(1):127-144. DOI:10.1088/0031-9155/58/1/127 · 2.76 Impact Factor
  • Source
    • "MRI-guided HIFU could also be particularly beneficial for treating brain disorders and transcranial applications, as it is noninvasive, does not cause bleeding, and does not damage surrounding tissue [6]. Transcranial therapy may be used for the temporary disruption of the blood-brain barrier (BBB), which will allow for delivering therapeutic agents and drugs to the brain [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent works on focused ultrasound (FUS) have shown great promise for cancer therapy. Researchers are continuously trying to improve system performance, which is resulting in an increased complexity that is more apparent when using multi-element phased array systems. This has led to significant efforts to reduce system size and cost by relying on system integration. Although ideas from other fields such as microwave antenna phased arrays can be adopted in FUS, the application requirements differ significantly since the frequency range used in FUS is much lower. In this paper, we review recent efforts to design efficient power monitoring, phase shifting and output driving techniques used specifically for high intensity focused ultrasound (HIFU).
    Sensors 12/2011; 11(1):539-56. DOI:10.3390/s110100539 · 2.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcranial focused ultrasound (FUS) and microbubble contrast agent, applied at parameters known to transiently increase blood-brain barrier permeability, were tested for the potential to stimulate hippocampal neurogenesis. In adult mice, FUS treatment significantly increased the number of proliferating cells and newborn neurons in the dentate gyrus of the dorsal hippocampus. This provides evidence that FUS with microbubbles can stimulate hippocampal neurogenesis, a process involved in learning and memory and affected in neurological disorders, such as Alzheimer's disease.
    Brain Stimulation 03/2014; 7(2):304-7. DOI:10.1016/j.brs.2013.12.012 · 4.40 Impact Factor
Show more